Skip to main content
SpringerLink
Log in

Psoriasis

  • Chapter
Therapie der Hautkrankheiten

Zusammenfassung

Die Psoriasis ist eine genetisch verankerte, chronische Dermatose, die weltweit bei Millionen von Menschen aller Rassen vorkommt; Männer und Frauen sind etwa gleichhäufig befallen. Die Inzidenz ist bei den Kaukasiern weißer Hautfarbe am höchsten, während in den Bevölkerungen Afrikas und Asiens die Erkrankung bei weitem seltener vorkommt. Die Prävalenz bei Mittel- bzw Nordeuropäern, eine Psoriasis zu entwickeln, beträgt ca. 2,8%; insgesamt ca. 0,5–1% der deutschen Bevölkerung sind wegen einer Psoriasis in ärztlicher Behandlung bzw. Kontrolle. In tropischen Klimazonen ist die Psoriasis extrem selten. Die Erkrankung zeigt eine familiäre Häufung, ohne regelmäßigen, klar erkennbaren Erbgang. Bei zweieiigen Zwillingen ist die Chance, daß beide Kinder eine Psoriasis entwickeln, ca. 20%, bei eineiigen Zwillingen > 60%.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Gupta MA, Schork NJ, Gupta AK, Ellis CN (1993) Alcohol intake and treatment responsiveness of psoriasis: A prospective study. J Am Acad Dermatol 28: 730–732

    PubMed  CAS  Google Scholar 

  • Abels DJ, Kattan-Byron J (1985) Psoriasis treatment at the Dead Sea: A natural selective ultraviolet photo-therapy. J Am Acad Dermatol 12: 639–643

    PubMed  CAS  Google Scholar 

  • Beiteke U, Budde J, Lentner A et al. (1988) Multiple eruptive keratoses and squamous cell carcinomata following PUVA therapy of more than 11 years. Photodermatology 5: 274–276

    PubMed  CAS  Google Scholar 

  • Bergner T, Przybilla B (1992) Malignant melanoma in association with phototherapy. Dermatology 184: 59–61

    PubMed  CAS  Google Scholar 

  • Boer J, Schothorst AA, Boom B et al. (1982) Influence of water and salt solutions on UVB irradiation of normal skin and psoriasis: Arch Dermatol Res 273: 247–259

    PubMed  CAS  Google Scholar 

  • Boer J, Schothorst AA, Suurmond D (1980) UV-B phototherapy of psoriasis. Dermatologica 161: 250–258

    PubMed  CAS  Google Scholar 

  • Brynzeel I, Bergman W, Hartevelt HM et al. (1991) High „single-dose“ European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 124: 49–55

    Google Scholar 

  • Calzavara P, Ortel B, Carlino A et al. (1992) Phototoxic reactions and treatment schedules in bath PUVA therapy. Photochem Photobiol 55: 38

    Google Scholar 

  • Diffey BL, Larkö O, Swanbeck G (1982) UV-B doses received during different outdoor activities and UV-B treatment of psoriasis. Br J Dermatol 106: 33–41

    PubMed  CAS  Google Scholar 

  • Diffey BL, DeBerker DAR, Saunders PJ, Farr PM (1993) A device for phototesting patients before PUVA-therapy. Br J Dermatol 129: 700–703

    PubMed  CAS  Google Scholar 

  • Eells LD, Wolff JM, Garloff J, Eaglstein WH (1984) Comparison of suberythemogenic and maximally aggressive ultraviolet B therapy for psoriasis. J Am Acad Dermatol 11: 105–110

    PubMed  CAS  Google Scholar 

  • Flindt-Hansen H, McFadden N, Eeg-Larsen T, Thune P (1991) Effect of a new narrow-band UVB lamp on photocarcinogenesis in mice. Acta Derm Venereol 71: 245–248

    PubMed  CAS  Google Scholar 

  • Green C, Ferguson J, Lakshmipathi T, Johnson BE (1988) 311 nm UV-B phototherapy–an effective treatment for psoriasis. Br J Dermatol 119: 691–696

    Google Scholar 

  • Green C, Lakshimpathi T, Johnson BE, Ferguson J (1992) A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. Br J Dermatol 127: 5–9

    PubMed  CAS  Google Scholar 

  • Gunnarskog JG, Kalen AJ, Lindelof BG et al. (1993) Psoralen photochemotherapy ( PUVA) and pregnancy. Arch Dermatol 128: 320–323

    Google Scholar 

  • Henseler T, Christophers E, Hönigsmann H, Wolff K (1987) Skin tumors in the European PUVA study. Eight-year follow up of 1643 patients treated with PUVA for psoriasis. J Am Acad Dermatol 16: 108–116

    PubMed  CAS  Google Scholar 

  • Hölzle E, Plewig G (1986) Biologische Wirkungen und Risiken des langwelligen ultravioletten Lichts. Hautarzt 37: 290–294

    Google Scholar 

  • Iest J, Boer J (1989) Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 120: 665–670

    PubMed  CAS  Google Scholar 

  • Jung EG (1988) Schwere Zwischenfälle mit SUP und PUVA. Akt Dermatol 14: 323–325

    Google Scholar 

  • Kanzler MH, Gorsulowsky DC (1993) Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis. Br J Dermatol 129: 310–314

    PubMed  CAS  Google Scholar 

  • Krutmann J (1991) Dermatologische Phototherapie. Hautarzt 42: 407–414

    PubMed  CAS  Google Scholar 

  • Larkö O, Swanbeck G (1982) Is UVB treatment of psoriasis safe? A study of extensively UVB-treated psoriasis patients compared with a matched control group. Acta Derm Venereol 62: 507–512

    PubMed  Google Scholar 

  • Lauharanta J, Juvakoski T, Lassus A (1981) A clinical evaluation of the effects of an aromatic retinoid ( Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis. Br J Dermatol 104: 325–332

    PubMed  CAS  Google Scholar 

  • Lindelöf B, Sigurgeirson B, Tegner E et al. (1991) PUVA and Cancer: a large scale epidemiological study. Lancet 338: 91–93

    PubMed  Google Scholar 

  • Lowe JG, Ferguson J (1988) Which emollients should be used during phototherapy (UVB)/photochemotherapy (PUVA) for psoriasis? A study of emollient effect on minimal erythema (MED) and phototoxic (MPD) doses. Br J Dermatol 119 [Suppl 33]: 52–53

    Google Scholar 

  • Lowe NJ, Wortzman MS, Breeding J et al. (1983) Coal tar phototherapy for psoriasis reevaluated: erythemogenic versus suberythemogenic ultraviolet with a tar extract in oil and crude coal tar. J Am Acad Dermatol 8: 781–789

    PubMed  CAS  Google Scholar 

  • Millar B, Green C, Ferguson J et al. (1989) A study of the photodegradation of leukotriene at by ultraviolet irradiation (UVB, UVA ). Br J Dermatol 120: 145–152

    PubMed  CAS  Google Scholar 

  • Orfanos CE, Steigleder GK, Pullmann H et al. (1979) Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis. Acta Derm Venereol 59: 241–244

    PubMed  CAS  Google Scholar 

  • Ortel B, Perl S, Dinaciyan T et al. (1993) Comparison of narrow-band (311 nm) UVB and broadband UVA after oral bath-water 8-methoxypsoralen in the treatment of psoriasis. J Am Acad Dermatol 29: 736–740

    PubMed  CAS  Google Scholar 

  • Paramsothy Y, Collins M, Lawrence CM (1988) Effect of UVB therapy and a coal tar bath on short contact dithranol treatment for psoriasis. Br J Dermatol 118: 783–789

    PubMed  CAS  Google Scholar 

  • Petrozzi JW, Barton JO, Kaidbey KK, Kligman AM (1978) Updating the Goeckerman regimen for psoriasis. Br J Dermatol 98: 437–444

    PubMed  CAS  Google Scholar 

  • Pham CT, Koo YM (1993) Plasma levels of 8-methoxypsoralen after topical paint PUVA. J Am Acad Dermatol 28: 460–466

    PubMed  CAS  Google Scholar 

  • Sakuntabhai A, Diffey BL, Farr PM (1993) Response of psoriasis to psoralen-UVB phototherapy. Br J Dermatol 128: 296–300

    PubMed  CAS  Google Scholar 

  • Schwarz T (1988) Die Bedeutung epidermaler Zytokine in der UV-induzierten Immunsuppression. Hautarzt 39: 642–646

    PubMed  CAS  Google Scholar 

  • Seppälä J, Laulainen M, Reunala T (1988) Comparison of etretinate (Tigason®) and parenteral gold in the treatment of psoriatic arthropathy. Clin Rheumatol 7: 498–503

    PubMed  Google Scholar 

  • Slaper H, Schothorst AA, van der Leun JC (1986) Risk evaluation of UVB therapy for psoriasis: comparison of calculated risk for UVB therapy and observed risk in PUVA-treated patients. Photodermatology 3: 271–283

    PubMed  CAS  Google Scholar 

  • Snellman E, Lauharanta J, Reunanen A et al. (1993) Effect of heliotherapy on skin and joint symptoms in psoriasis: a 6-month follow-up study. Br J Dermatol 128: 172–177

    PubMed  CAS  Google Scholar 

  • Stern RS, Zierler S, Parrish JA (1980) Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet I: 732–735

    Google Scholar 

  • Stern RS, Laird N, Melski J et al. (1984) Cutaneous squamous cell carcinoma in patients treated with PUVA. N Engl J Med 310: 1156–1161

    PubMed  CAS  Google Scholar 

  • Stern RS, Scotto J, Fears TR (1985) Psoriasis and succeptibility to nonmelanoma skin cancer. J Am Acad Dermatol 12: 65–73

    Google Scholar 

  • Stern RS, Gange RW, Parrish J et al. (1986) Contribution of topical tar oil to ultraviolet B phototherapy for psoriasis. J Am Acad Dermatol 14: 742–747

    PubMed  CAS  Google Scholar 

  • Storbeck K, Hölzle E, Schurer N (1993) Narrow-band UVB (311 nm) versus conventional broadband UVB with and without dithranol in phototherapy for psoriasis. J Am Acad Dermatol 28: 227–231

    PubMed  CAS  Google Scholar 

  • Studniberg HM, Weller P (1993) PUVA, UVB, psoriasis and nonmelanoma skin cancer. J Am Acad Dermatol 29: 1013–1022

    PubMed  CAS  Google Scholar 

  • Swinehart JM, Lowe NJ (1991) UVABA therapy for psoriasis. J Am Acad Dermatol 24: 594–597

    PubMed  CAS  Google Scholar 

  • Takashima A, Ymamato K, Kimura S et al. (1991) Allergic contact and photocontact dermatitis due to psoralens in patients with psoriasis treated with topical PUVA. Br J Dermatol 124: 37–42

    PubMed  CAS  Google Scholar 

  • Williams REA, Tillman DM, White SI et al. (1992) Reexamining crude coal tar treatment for psoriasis. Br J Dermatol 126: 608–610

    PubMed  CAS  Google Scholar 

  • Ashton RE, Andre P, Lowe NJ, Whitefield M (1983) Anthralin: historical and current perspectives. J Am Acad Dermatol 9: 173–192

    PubMed  CAS  Google Scholar 

  • Brody I, Johansson A (1977) A topical treatment program for psoriasis with low anthralin concentrations. J Cutan Pathol 4: 233–243

    PubMed  CAS  Google Scholar 

  • Cripps DJ, Lowe NJ (1979) Photochemotherapy for psoriasis remission times. Psoralens and UV-A and combined photochemotherapy with anthralin. Clin Exp Dermatol 4: 477–483

    PubMed  CAS  Google Scholar 

  • Downey DJ, Finlay AY (1986) Combined short-contact crude coal tar and dithranol therapy for psoriasis. Clin Exp Dermatol 11: 498–501

    PubMed  CAS  Google Scholar 

  • Duhra P, Ryatt KS (1988) Lack of additive effect of coal tar combined with dithranol for psoriasis. Clin Exp Dermatol 13: 72–73

    PubMed  CAS  Google Scholar 

  • Farber EM, Harris DR (1970) Hospital treatment of psoriasis. A modified anthralin program. Arch Dermatol 101: 381–389

    PubMed  CAS  Google Scholar 

  • Haustein UF, Lohrisch I (1986) Irritant potential of dithranol. Dermatologica 173: 288–293

    PubMed  CAS  Google Scholar 

  • Hellier FF, Whitefield M (1967) The treatment of psoriasis with triacetoxyanthracene. Br J Dermatol 79: 491–496

    PubMed  CAS  Google Scholar 

  • Hodgson C, Mell E (1970) Clinical comparison between triacetoxyanthracene and dithranol pastes in the treatment of chronic psoriasis. Br J Dermatol 83: 397–401

    PubMed  CAS  Google Scholar 

  • Kammerau B, Zesch A, Schaefer H (1975) Absolute concentrations of dithranol and triacetoxydithranol in the skin layers after local treatment: In vivo investigations with four different types of pharmaceutical vehicles. J Invest Dermatol 64: 145–149

    Google Scholar 

  • Kemény L, Ruzicka T, Braun-Falco O (1990) Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 3: 1–20

    PubMed  Google Scholar 

  • Kingston T, Marks R (1983) Irritant reactions to dithranol in normal subjects and psoriatic patients. Br J Dermatol 108: 307–313

    PubMed  CAS  Google Scholar 

  • Krebs A, Schaltegger H (1969) Untersuchungen zur Strukturspezifität der Psoriasisheilmittel Chrysarobin und Dithranol. Hautarzt 20: 204–209

    PubMed  CAS  Google Scholar 

  • Krebs A, Schaltegger H, Schaltegger A (1981) Structure specificity of the antipsoriatic anthrones. Br J Dermatol 105: 6–11

    PubMed  CAS  Google Scholar 

  • Lawlor F, Hudson C (1982) Allergy to dithranol. Contact Dermatitis 8: 137–138

    PubMed  CAS  Google Scholar 

  • Lawrence CM, Shuster S (1985) Mechanism of anthralin inflammation. 1. Dissociation of response to clobetasol and indomethacin. Br J Dermatol 113: 107–115

    Google Scholar 

  • Lawrence CM, Shuster S, Collins M et al. (1987) Reduction of anthralin inflammation by potassium hydroxide and Teepol. Br J Dermatol 116: 171–177

    PubMed  CAS  Google Scholar 

  • Lowe NJ, Breeding J (1981) Anthralin, different concentration effects on epidermal cell DNA synthesis rates in mice and clinical responses in human psoriasis. Arch Dermatol 117: 698–700

    PubMed  CAS  Google Scholar 

  • Marsden JR, Coburn PR, Marks J, Shuster S (1983) Measurement of the response of psoriasis to short-term application of anthralin. Br J Dermatol 109: 209–218

    PubMed  CAS  Google Scholar 

  • Montes LF, Wilborn WH, Brody I (1979) Low strength anthralin in psoriasis. J Cutan Pathol 6: 445–456

    PubMed  CAS  Google Scholar 

  • Morison WL, Parrish JA, Fitzpatrick TB (1978) Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis. Br J Dermatol 98: 125–132

    PubMed  CAS  Google Scholar 

  • Müller R, Naumann E, Detmar M et al. (1987) Stabilität von Cignolin ( Dithranol) in teerhaltigen Salben mit und ohne Salicylsäurezusatz. Hautarzt 38: 107–111

    PubMed  Google Scholar 

  • Mustakallio KK (1981) Irritation, staining and antipsoriatic activity of 10-acyl analogues of anthralin. Br J Dermatol 105: 23–27

    PubMed  CAS  Google Scholar 

  • Mustakallio KK (1992) The history of dithranol and related hydroxyanthrones, their efficacy, side effects, and different regimens employed in the treatment of psoriasis. Acta Derm Venereol 172: 7–9

    CAS  Google Scholar 

  • Orfanos CE, Runne U (1976) Systemic use of a new retinoid with and without local dithranol treatment in generalised psoriasis. Br J Dermatol 95: 101–103

    PubMed  CAS  Google Scholar 

  • Orfanos CE, Steigleder GK (1976) Psoriasis-Therapie mit Cigudin (Dihydroxyanthranol). Das Kölner CSVTherapie-Schema Z. Hautkr. 51: 473–480

    CAS  Google Scholar 

  • Pearlman DL, Burns J, Cannon TC et al. (1984) Paper-tape occlusion of anthralin paste. Arch Dermatol 120: 625–630

    PubMed  CAS  Google Scholar 

  • Ponec-Waelsch, Hulsebosch HJ (1974) Further studies on interaction between anthralin, salicylic acid, and zinc oxide in paste. Arch Dermatol Forsch 294: 141–152

    Google Scholar 

  • Przybilla B, Kaudewitz P, Bieber K (1989) Harnstoff in Kombination mit Dithranol zur Therapie der Psoriasis vulgaris. Hautarzt 40: 54–57

    PubMed  Google Scholar 

  • Pullmann H, Enderer K, Steigleder GK (1981) Cytokinetic effects of anthralin on psoriatic keratinocytes. Br J Dermatol 105: 55–56

    PubMed  Google Scholar 

  • Raab WG (1976) Dithranol (anthralin) versus triacetoxyanthracene. Br J Dermatol 95: 193–196

    PubMed  CAS  Google Scholar 

  • Reshad H, Barth JH, Darlex CR, Baker H (1984) Does UV-A potentiate „short contact“ dithranol therapy? Br J Dermatol 111: 155–158

    PubMed  CAS  Google Scholar 

  • Runne U, Kunze J (1982) Short-duration („minutes“) therapy with dithranol for psoriasis: a new outpatient regimen. Br J Dermatol 106: 135–139

    PubMed  CAS  Google Scholar 

  • Runne U, Kunze J (1983) Psoriasis: Die praktische Anwendung der Minuten Therapie mit Dithranol ( Anthralin ). Z Hautkr 58: 219–229

    CAS  Google Scholar 

  • Schaefer H, Farber EM, Goldberg L, Schalla W (1980) Limited application period for dithranol in psoriasis. Br J Dermatol 102: 571–573

    PubMed  CAS  Google Scholar 

  • Schalla W, Bauer E, Schaefer H (1981) Skin perme- ability of anthralin. Br J Dermatol 105: 104–108

    PubMed  CAS  Google Scholar 

  • Seville RH (1975) Simplified dithranol treatment for psoriasis. Br J Dermatol 93: 205–208

    PubMed  CAS  Google Scholar 

  • Seville RH (1976) Relapse rate of psoriasis worsened by adding steroids to a dithranol regime. Br J Dermatol 95: 643–646

    PubMed  CAS  Google Scholar 

  • Seville RH (1986) Dithranol-based therapies. In: Kerkhof PCM van de (ed) Textbook of psoriasis. Churchill Livingstone, Edinburgh, pp 178–189

    Google Scholar 

  • Seville RH, Walker GB, Whitefield M (1979) Dithranol cream. Br J Dermatol 100: 457–458

    Google Scholar 

  • Statham BN, Ryatt KS, Rowell NR (1984) Short contact dithranol therapy — a comparison with the Ingram regime. Br J Dermatol 110: 703–708

    PubMed  CAS  Google Scholar 

  • Steigleder GK, Schulze H (1984) Ein neues Kölner Therapie-Schema: Zusatz von Teer zur Cignolin-Salicylsäure-Weisse Vaselin-(CSV)-Therapie ( TCSV) der Psoriasis vulgaris. Z Hautkr 59: 188–192

    PubMed  CAS  Google Scholar 

  • Steigleder GK, Schumann H, Lennartz KJ (1973) Autoradiographic in vitro examination of psoriatic skin before, during and after dithranol treatment. Arch Dermatol Forsch 246: 231–235

    PubMed  CAS  Google Scholar 

  • Swinehart JM, Lowe NJ (1991) UVABA therapy for psoriasis. J Am Acad Dermatol 24: 594–597

    PubMed  CAS  Google Scholar 

  • Whitelfield M (1981) Pharmaceutical formulations of anthralin. Br J Dermatol 105: 28–32

    Google Scholar 

  • Williamson DM (1983) Treatment of chronic psoriasis by psoradrate (0.1% dithranol in a 17% urea base) applied under occlusion. Clin Exp Dermatol 8: 287–290

    PubMed  CAS  Google Scholar 

  • Wilson PD, Ive FA (1980) Dithrocream in psoriasis. Br J Dermatol 102: 105–106

    Google Scholar 

  • Young E, Van Weelden H (1987) Treatment of psoriasis with a combination of dithranol and coal tar. Br J Dermatol 116: 281–282

    PubMed  CAS  Google Scholar 

  • Berth-Jones J, Chu AC, Dodd WAH, Ganpule M et al. (1992) A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 127: 266–271

    PubMed  CAS  Google Scholar 

  • Bhalla AK, Amento EP, Serog B. Glimcher LH (1984) 1,25-Dihydroxyvitamin D3 inhibits antigen-induced t-cell activation. J Immunol 133: 1748–1754

    Google Scholar 

  • Binderup L, Bramm E (1988) Effects of a novel Vitamin D analogue MC 903 on cell proliferation and differentiation in vitro and on Calcium metabolism in vivo. Biochem Pharmacol 37: 889–895

    PubMed  CAS  Google Scholar 

  • Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G et al. (1992) Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 26: 736–743

    PubMed  CAS  Google Scholar 

  • De Mare S, De Jong EGJM, van de Kerkhof PCM (1990) DNA content and K,8.12 binding of the psoriatic lesion during treatment with the vitamin D3 analogue MC 903 and betamethasone. Br J Dermatol 123: 291–295

    Google Scholar 

  • Frappaz A, Thivolet J (1993) Calcipotriol in combination with PUVA: A randomized double-blind placebo study in severe psoriasis. Eur J Dermatol 3: 351–354

    Google Scholar 

  • Gray JD, Bottomley W, Layton AM et al. (1992) The use of calcipotriol in HIV-related psoriasis. Clin Exper Dermatol 17: 342–343

    CAS  Google Scholar 

  • Healy E, Mulcahy F, Barnes L (1993) The spectrum of psoriasis in an irish HIV population. J Europ Acad Dermatol Venereol 2: 253–257

    Google Scholar 

  • Kissmeyer A-M, Binderup L (1991) Calcipotriol (MC 903): Pharrnacokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3. Biochem Pharmacol 41: 1601–1606

    PubMed  CAS  Google Scholar 

  • Kragballe K (1990) Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. Dermatologica 181: 211–214

    PubMed  CAS  Google Scholar 

  • Kragballe K, Fogh K, Sogaard H (1991) Long-term efficacy and tolerability of topical calcipotriol in psoriasis. Results of an open study. Acta Derm Venereol 71: 475–478

    Google Scholar 

  • Morimoto S, Kumahara Y (1985) A patient with psoriasis cured by la-hydroxyvitamin D3. Med J Osaka Univ 35: 51–54

    PubMed  CAS  Google Scholar 

  • Muller K, Svenson M, Bendtzen K (1988) la,25Dihydroxyvitamin D3 and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitro. Immunol Letters 17: 361–366

    Google Scholar 

  • Nishimura M, Hori Y, Nishiyama S, Nakamizo Y (1993) Topical la,24(R)-dihydroxyvitamin D3 for the treatment of psoriasis. Review of the literature. Eur J Dermatol 3: 255–261

    Google Scholar 

  • Weinstein GD, White GM (1993) An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 28: 454–459

    PubMed  CAS  Google Scholar 

  • Ashton RE, Millward-Sadler GH, White JE (1982) Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 79: 229–232

    PubMed  CAS  Google Scholar 

  • Burkhart CG (1980) Treatment of psoriasis with methotrexate and folinic acid. J Am Assoc Dermatol 3: 207

    CAS  Google Scholar 

  • Cream JJ, Poll DS (1980) The effect of methotrexate and hydroxyurea on neutrophil chemotaxis. Br J Dermatol 102: 557–563

    PubMed  CAS  Google Scholar 

  • Dooren-Greebe RJ van, Kuijpers ALA, Mulder J et al. (1994) Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 130: 204–210

    PubMed  Google Scholar 

  • Duhra P (1993) Treatment of gastrointestinal symptoms associated with methotrexate treatment for psoriasis. J Am Acad Dermatol 28: 4566–469

    Google Scholar 

  • Hendel L, Hendel J, Johnsen A, Gudmand-Hoyer E (1982) Intestinal function and methotrexate aborption in psoriatic patients. Clin Exp Dermatol 7: 491–498

    PubMed  CAS  Google Scholar 

  • Kerkhof PCM van de (1986) Methotrexate. In: Mier PD, van de Kerkhof PCM (eds) Textbook of psoriasis. Churchill Livingstone, Edinburgh, pp 233–251

    Google Scholar 

  • Kerkhof PCM van de, Mali JWH (1982) Methotrexate maintenance following Ingram therapy in difficult psoriasis. Br J Dermatol 106: 623–627

    Google Scholar 

  • Kerkhof PCM van de, Hoefnagels WHL, van Haelst UJGM, Mali JWH (1985) Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol 10: 194–200

    Google Scholar 

  • Kragballe K, Zachariae E, Zachariae H (1982) Methotrexate in psoriatic arthritis: A retrospective study. Acta Dermatovenereol 63: 165–167

    Google Scholar 

  • Mali-Gerrits MGH, Gaasbeck D, Boezeman J, van de Kerkhof PCM (1991) Psoriasis therapy and the risk of skin cancers. Clin Exper Dermatol 16: 85–89

    CAS  Google Scholar 

  • Miller JA, Dodd H, Rustin MHA et al. (1985) Ultrasound as a screening procedure for methotrexate-induced hepatic damage in severe psoriasis. Br J Dermatol 113: 699–705

    PubMed  CAS  Google Scholar 

  • Mitchell D, Johnston RJ, Testa HJ et al. (1987) Ultrasound and radionuclide scans — poor indicators of liver damage in patients treated with methotrexate. Clin Exp Dermatol 12: 243–245

    PubMed  CAS  Google Scholar 

  • Nyfors A, Jensen H (1983) Frequency of malignant neoplasms in 248 long-term methotrexate treated psoriatics. Dermatologica 167: 260–261

    PubMed  CAS  Google Scholar 

  • Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD (1988) Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 19: 145–156

    PubMed  Google Scholar 

  • Stern RS, Zierler S, Parrish JA (1982) Methotrexate used for psoriasis and the risk of noncutaneous and cutaneous malignancy. Cancer 50: 869–872

    PubMed  CAS  Google Scholar 

  • Walsdorfer U, Christophers E, Schröder JM (1983) Methotrexate inhibits polymorphonuclear leucocyte chemotaxis in psoriasis. Br J Dermatol 108: 451–456

    PubMed  CAS  Google Scholar 

  • Weinstein GD, Frost P (1971) Methotrexate for psoriasis: A new therapeutic schedule. Arch Dermatol 103: 33–38

    Google Scholar 

  • Zachariae H, Kragballe K, Sogaard H (1980) Methotrexate induced liver cirrhosis: studies including serial liver biopsies during continued treatment. Br J Dermatol 102: 407–412

    PubMed  CAS  Google Scholar 

  • Zachariae H, Sogaard H (1987) Methotrexate induced liver cirrhosis. A follow-up. Dermatologica 175: 178–182

    Google Scholar 

  • Burge S, Ryan T (1985) Diffuse hyperostosis associated with etretinate. Lancet II: 397–398

    Google Scholar 

  • Dubertret L, Chastang C, Beylot C (1985) Maintenance treatment of psoriasis by Tigason: a double-blind, randomized clinical trial. Br J Dermatol 113: 323–330

    PubMed  CAS  Google Scholar 

  • Goldfarb MT, Ellis CN, Gupta AK et al. (1988) Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 18: 665–662

    Google Scholar 

  • Gollnick H, Bauer R, Brindley C et al. (1988) Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetik results of a german multicenter study. J Am Acad Dermatol 19: 458–469

    PubMed  CAS  Google Scholar 

  • Gollnick H, Orfanos CE (1991) Clinical efficacy of retinoids: European experiences. In: Roenigk HH Jr, Maibach HI (eds) Psoriasis. Dekker, Basel, pp 725–748

    Google Scholar 

  • Gollnick H, Rinck G, Bitterling T, Orfanos CE (1990) Pharmakokinetik von Etretinat, Acitretin and 13-cisAcitretin: neue Ergebnisse and Nutzen der Blutspiegel-orientierten klinischen Anwendung. Z Hautkr 65: 40–50

    PubMed  CAS  Google Scholar 

  • Gollnick H, Zaun H, Ruzicka T et al. (1993) Relapse rate of severe generalized psoriasis after treatment with acitretin or etretinate. Results of the first randomized double-blind multicenter halfyear follow-up study. Eur J Dermatol 3: 442–446

    Google Scholar 

  • Korstanje MJ, van de Staak WJBM (1990) Combination-therapy cyclosporin A-etretinate for psoriasis. Clin Exp Dermatol 15: 172–173

    PubMed  CAS  Google Scholar 

  • Kullavanijaya P, Kulthanan K (1993) Clinical efficacy and side effects of acitretin on the disorders of keratinization: A one-year study. J Dermatol 20: 501–506

    PubMed  CAS  Google Scholar 

  • Larsen FG, Jakobsen P, Knudsen J (1993) Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 100: 623–627

    PubMed  CAS  Google Scholar 

  • Lassus A, Geiger JM, Nyblom M et al. (1987) Treatment of severe psoriasis with etretin (Ro 10–1670). Br J Dermatol 117: 333–341

    PubMed  CAS  Google Scholar 

  • Laugier JP, Berbis P, Brindley C et al. (1989) Determination of acitretin and 13-cis-acitretin in skin. Skin Pharamacol 2: 181–186

    CAS  Google Scholar 

  • Lauharanta J, Geiger JM (1989) A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 121: 107–112

    PubMed  CAS  Google Scholar 

  • Ledo A, Martin M, Geiger JM, Marron JM (1988) Acitretin (Ro 10–1670) in the treatment of severe psoriasis. Acta Derm Venereol 69: 35–10

    Google Scholar 

  • Melnik B, Gluck S, Jungblut RM, Goerz G (1987) Retrospective radiographic study of skeletal changes after long-term etretinate therapy. Br J Dermatol 116: 207–212

    PubMed  CAS  Google Scholar 

  • Orfanos CE, Bauer R (1983) Evidence for antiinflammatory activities of oral synthetic retinoids: experimental findings and clinical experience. Br J Dermatol 109: 55–60

    PubMed  CAS  Google Scholar 

  • Orfanos CE, Ehlert R, Gollnick H (1987) The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs 34: 459–503

    PubMed  CAS  Google Scholar 

  • Orfanos CE, Goerz G (1978) Orale Psoriasis-Therapie mit einem neuen aromatischen Retinoid (Ro 10–9359) Eine multizentrische kontrollierte Studie an 291 Patienten in der Bundesrepublik. Dtsch Med Wochenschr 103: 195–199

    PubMed  CAS  Google Scholar 

  • Orfanos CE, Stadler R, Gollnick H, Tsambaos D (1985) Current developments of oral retinoid therapy with three generations of drugs. In: Orfanos CE (ed) Current problems in dermatology. Karger, Basel, pp 33–50

    Google Scholar 

  • Prendiville J, Binghan EA, Burrows D (1986) Premature epiphyseal closure–A complication of etretinate therapy in children. J Am Acad Dermatol 15: 1259–1262

    PubMed  CAS  Google Scholar 

  • Rinck G, Gollnick H, Orfanos CE (1989) Duration of contraception after etretinate. Lancet I: 845–846

    Google Scholar 

  • Ruzicka T, Sommerburg C, Braun-Falco O et al. (1990) Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 126: 482–486

    PubMed  CAS  Google Scholar 

  • Shah IA, Whiting PH, Omar G et al. (1993) The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin. Br J Dermatol 129: 395–398

    PubMed  CAS  Google Scholar 

  • Webber IR, Back DJ (1993) Effect of etretinate on cyclosporin metabolism in vitro. Br J Dermatol 128: 42–44

    PubMed  CAS  Google Scholar 

  • Bunse T, Schulze H-J, Mahrle G (1990) Lokale Anwendung von Cyclosporin bei Psoriasis vulgaris. Z Hautkr 65: 538–542

    PubMed  CAS  Google Scholar 

  • Cooper KD, Baadsgaard O, Ellis CN et al. (1990) Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis. J Invest Dermatol 94: 649–656

    PubMed  CAS  Google Scholar 

  • Cooper KD, Voorhees JJ, Fisher GJ et al. (1990) Effects of cyclosporine on immunologic mechanisms in psoriasis. J Am Acad Dermatol 23: 1318–1328

    PubMed  CAS  Google Scholar 

  • Christophers E, Mrowietz U, Henneicke HH et al. (1992) Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. J Am Acad Dermatol 26: 86–90

    PubMed  CAS  Google Scholar 

  • Fradin MS, Ellis CN, Voorhees JJ (1990) Management of patients and side effects during cyclosporine therapy for cutaneous disorders. J Am Acad Dermatol 23: 1265–1275

    PubMed  CAS  Google Scholar 

  • Griffiths CEM, Powles AV, Baker BS et al. (1987) Comparison of psoriasis treated with cyclosporin alone or cyclosporin and clobetasol proprionate. Br J Dermatol 117: 35–36

    Google Scholar 

  • Griffiths CEM, Powles AV, McFadden J et al. (1989) Long-term cyclosporin for psoriasis. Br J Dermatol 120: 253–260

    PubMed  CAS  Google Scholar 

  • Grossman RM, Delaney RJ, Brinton EA et al. (1991) Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol 25: 648–651

    PubMed  CAS  Google Scholar 

  • Gupta AK, Matteson EJ, Ellis CN et al: (1989) Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol 125: 507–510

    PubMed  CAS  Google Scholar 

  • Gupta AK, Ellis CN, Nickoloff BJ et al. (1990) Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. Arch Dermatol 12: 339–350

    Google Scholar 

  • Ellis CN, Gorsulowsky DC, Hamilton TA et al. (1986) Cyclosporine improves psoriasis in a double-blind study: J Am Med Assoc 256: 3110–3116

    CAS  Google Scholar 

  • Ellis CN, Fradin MS, Messana JM et al. (1991) Cyclosporine for plaque-type psoriasis. N Engl J Med 324: 277–284

    PubMed  CAS  Google Scholar 

  • Hatfield SM, Roehm NW (1992) Cyclosporine and FK 506 inhibition of murine mast cell cytokine production. J Pharmacol Exp Ther 260: 680–688

    PubMed  CAS  Google Scholar 

  • Joost TV, Bos JD, Heule F et al. (1988) Low-dose cyclosporin A in severe psoriasis: a double-blind study. Br J Dermatol 118: 183–190

    PubMed  Google Scholar 

  • Korstanje MJ, van Breda Vriesman CJP, van de Staak WJBM (1990) Cyclosporine and methrotrexat: A dangerous combination. J Am Acad Dermatol 23: 320–321

    CAS  Google Scholar 

  • Krupp P, Monka C (1990) Side effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol 122: 47–56

    PubMed  Google Scholar 

  • Meinardi MMHM, De Rie MA, Bos JD (1990) Oral cyclosporin A is effective in clearing persistant pustulosis palmaris et plantaris. Acta Derm Venereol 70: 77–79

    PubMed  CAS  Google Scholar 

  • Mihatsch MJ, Wolff K (1992) Consensus Conference on cyclosporin A for psoriasis. Br J Dermatol 126: 621–623

    PubMed  CAS  Google Scholar 

  • Piscascia DD; Garden JM, Freinkel RK et al. (1987) Treatment of resistant severe psoriasis with systemic cyclosporine. J Am Acad Dermatol 17: 408–414

    Google Scholar 

  • Reitamo S, Mustakallio KK (1989) Cyclosporin in erythrodermic psoriasis. Acta Derm Venereol 146: 140–141

    CAS  Google Scholar 

  • Stiller MJ, Pak GH, Kenny C et al. (1992) Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. J Am Acad Dermatol 27: 434–438

    PubMed  CAS  Google Scholar 

  • Bittiner SB, Cartwright I, Tucker WFG, Bleehen SS (1988) A double-blind randomised, placebo-controlled trial of fish oil in psoriasis. Lancet I: 388–390

    Google Scholar 

  • Elias AN, Goodman MM, Rohan MK et al. (1993) Methimazole (2-mercapto 1-methyl-imidazole) in psoriasis — Results of an open trial. Dermatology 187: 26–29

    PubMed  CAS  Google Scholar 

  • Guzzo C, Benik K, Lazarus G et al. (1991) Treatment of psoriasis with piritrexim, a lipid-soluble folate antagonist. Arch Dermatol 127: 511–514

    PubMed  CAS  Google Scholar 

  • Henneicke-v. Zeppelin HH, Mrowietz U, Färber L et al. (1993) Highly purified omega-3-polyunsaturated fatty acids for topical treatment of psoriasis. Br J Dermatol 129: 713–717

    Google Scholar 

  • Kao NL, Rosenblate HJ (1993) 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol 28: 1017–1018

    Google Scholar 

  • Maurice PDL, Allen BR, Barkley ASJ et al. (1987) The effects of dietary supplementation with fish oil in psoriasis. Br J Dermatol 117: 599–606

    PubMed  CAS  Google Scholar 

  • Merk H, Goerz G, Runne U et al (1983) Cimetidine and chlorpheniramine in the treatment of psoriasis. Dermatologica 166: 94–96

    PubMed  CAS  Google Scholar 

  • Molin L, Thomsen K (1987): Thioguanine treatment in psoriasis. Acta Derm Venereol 67: 85–88

    PubMed  CAS  Google Scholar 

  • Nielsen HJ, Nielsen H, Georgson J (1991) Ranitidine for improvement of treatment-resistant psoriasis. Arch Dermatol 127: 270

    PubMed  CAS  Google Scholar 

  • Perkins W, Williams REA, Vestey JP et al. (1993) A multicentre 12-week open study of a lipidsoluble folate antagonist, piritrexim in severe psoriasis. Br J Dermatol 129: 584–589

    PubMed  CAS  Google Scholar 

  • Wallach D, Cottenol F (1982) Cimetidine versus placebo in the treatment of psoriasis. Dermatologica 165: 197–203

    PubMed  CAS  Google Scholar 

  • Witkamp L, Velthuis PJ, Verhaegh MEJM et al. (1993) An open prospective clinical trial with systemic ranitidine in the treatment of psoriasis. J Am Acad Dermatol 28: 778–781

    PubMed  CAS  Google Scholar 

  • Zackheim HS, Maibach RI (1988) Treatment of psoriasis with 6-thioguanine. Austr J Dermatol 29: 163–167

    CAS  Google Scholar 

  • Zackheim HS, Glogau RG, Fisher DA, Maibach HI (1994) 6-Thioguanine treatment of psoriasis: Experience in 81 patients: J Am Acad Dermatol 30: 452–458

    Google Scholar 

  • Allen BR (1992) Use of cyclosporin for psoriasis in HIV-positive patient. Lancet 339: 686

    PubMed  CAS  Google Scholar 

  • Duvic M (1990) Immunology of AIDS related to psoriasis. J Invest Dermatol 95 [Suppl]: 38S - 40S

    Google Scholar 

  • Duvic M, Johnson TM, Rapini RP et al. (1987) Acquired immunodeficiency syndrome-associated psoriasis and Reiter’s syndrome. Arch Dermatol 123: 1622–1632

    PubMed  CAS  Google Scholar 

  • Healy E, Mulcahy F, Barnes L (1993) The spectrum of psoriasis in an Irish HIV population. J Eur Acad Derm Venereol 2: 253–257

    Google Scholar 

  • Kaplan MH, Sadick NS, Wieder J et al. (1989) Antipsoriatic effect of zidovudine in HIV-associated psoriasis. J Am Acad Dermatol 20: 76–82

    PubMed  CAS  Google Scholar 

  • Sadick NS, McNutt NS, Kaplan MH (1990) Papulosquamous dermatoses of AIDS. J Am Acad Dermatol 22: 1270–1277

    PubMed  CAS  Google Scholar 

  • Stashower ME, Yeager JK, Smith KJ et al (1993) Cimetidine as therapy for treatment-resistant psoriasis in a patient with acquired immunodeficiency syndrome. Arch Dermatol 129: 848–850

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Hautklinik und Poliklinik, Klinikum Benjamin Franklin der Freien Universität Berlin, Hindenburgdamm 30, 12200, Berlin, Deutschland

    Prof. Dr. Prof. h.c. Constantin E. Orfanos & Prof. Dr. Claus Garbe

Authors
  1. Prof. Dr. Prof. h.c. Constantin E. Orfanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Claus Garbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Orfanos, C.E., Garbe, C. (1995). Psoriasis. In: Therapie der Hautkrankheiten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-97602-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-97602-5_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-97603-2

  • Online ISBN: 978-3-642-97602-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation